Education
About Us
Working with TipRanks
Follow Us
Pol Boudes Insider Profile
4 Followers
Pol Boudes, CMO at CymaBay Therapeutics, holds 0.00 shares in CymaBay Therapeutics (Ticker: CBAY), holds 7.54K shares in Protalix (Ticker: PLX), holds ― shares in Galectin Therapeutics (Ticker: GALT). Most recently, Pol Boudes ― shares of CymaBay Therapeutics on ― for an estimated value of ―.
Pol Boudes CymaBay Therapeutics (CBAY)CMO
CymaBay Therapeutics (CBAY)
CMO
Not Ranked
Pol Boudes has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Pol Boudes holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Pol Boudes
Pol Boudes's Trading History
CymaBay Therapeutics
―
―
―
$0.00
Protalix
Sep 04, 2025
Director
Uninformative Buy
―
$15.53K
Galectin Therapeutics
―
CMO
―
―
Amicus
―
CMO
―
$0.00
List of latest transactions for each holding click on a transaction to see Pol Boudes's performance on stock
You May Also Like
Pol Boudes insider profile FAQ
What is the percentage of profitable transactions made by Pol Boudes?
The percentage of profitable transactions made by Pol Boudes is ―.
What is the average return per transaction made by Pol Boudes?
The average return per transaction made by Pol Boudes is ―.
What stocks does Pol Boudes hold?
Pol Boudes holds: CBAY, PLX, GALT, FOLD stocks.
What was Pol Boudes’s latest transaction?
Pol Boudes latest transaction was an Uninformative Buy of ―.
What was Pol Boudes's most profitable transaction?
Pol Boudes’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Pol Boudes's role in CymaBay Therapeutics?
Pol Boudes's role in CymaBay Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.